CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

CG Oncology announced publication of Phase 3 BOND-003 Cohort C trial results for cretostimogene grenadenorepvec in treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The study demonstrated 75.5% complete response rates, median duration of response of 27.9 months, 89% bladder preservation at 12 months, and a favorable safety profile with no Grade 3+ adverse events.